TORONTO, May 13, 2020 – Today, Sinai Health, a significant centre for COVID-19 testing in Canada, will receive a donation from The Mammoth Foundation of key laboratory equipment to increase its COVID-19 detection capability. The Mammoth Foundation has donated testing equipment produced by genomics leader BGI Group, in addition to installation, training and logistics support. At the heart of this donation, among other equipment, is the MGISP-960 automated viral RNA extraction and sample prepara...

May 6, 2020 BGI Genomics and MGI, members of the BGI Group, are jointly providing a high throughput, clinically validated workflow to address major bottlenecks for large-scale COVID-19 testing. The solution includes BGI’s Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2, which is the authorized device by Health Canada, as well as MGI’s MGIEasy Nucleic Acid Extraction Kit and MGISP-960RS Automated Sample Preparation System. BGI Genomics announced today that its subsidiary BGI Americas...

PARIS, April 17, 2020 -- MGI, a global life science technology company of BGI Group, has signed an agreement with the Health Ministry of France to provide equipment and materials to enable testing of 2 million people throughout the country for COVID-19. MGI is working with hospitals around France to deliver the urgently needed testing supplies and rapidly scale up capacity to 40,000 tests per day for the population. “I know that I can count on the full mobilization of BGI Group to supp...

MGI has announced a major upgrade for DNBSEQ-G50 with improvements to flexibility, turnaround time and performance. The original FC (Flow Cell) with 300M total reads is upgraded to FCL (Flow Cell Large) with 500M total reads, and a new FCS (Flow Cell Small) has been released with total reads of 100M. In addition, a longer read length of PE150 has been released, and the sequencing chemistry has been optimized to provide shorter turnaround time and better data performance. With this upgrade,...

Abu Dhabi, United Arab Emirates; March 29, 2020: Group 42 (G42), the leading technology company based in Abu Dhabi, and global genomics leader BGI announced today the launch of a new massive-throughput laboratory built to address the need for population-scale detection and diagnosis of COVID-19 in the United Arab Emirates. The lab is capable of conducting tens of thousands RT-PCR tests per day and is the first in the world of this scale to be operational outside of China. The lab showcases the ...